Approved for use through 10/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for form 1449B/PTO Application Number 10/580,601 INFORMATION DISCLOSURE May 25, 2006 Filing Date STATEMENT BY APPLICANT Matthias AUSTEN et al. First Named Inventor 1633 Art Unit Fereydoun Ghotb Sajjadi (Use as many sheets as necessary) Examiner Name WFICKM-0058 Attorney Docket Number

		NON PATENT LITERATURE DOCUMENTS	
Examiner	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
D.C./		CHEN et al., "Exploring Stem Cell Biology With Small Molecules", Mol. BioSyst., 2006, Volume 2, pp. 18-24.	
/D.C./		KROON et al., "Pancreatic Endoderm Derived From Human Embryonic Stem Cells Generates Glucose-Resonsive Insulin-Secreting Cells in vivo", Nature Biotechnology, April, 2008, Volume 26, no. 4, pp. 443-452.	
/D.C./		JING et al., "GFRα-3 Are Two New Receptors for Ligands of the GDNF Family", Journal of Biological Chemistry, 1997, Volume 272, no. 52, pp. 33111-33117.	
/D.C./		CHEN et al., "Reversine Increases The Plasticity of Lineage-committed Mammalian Cells", PNAS, June, 2007, Vol. 104, no. 25, pp. 10482-10487.	
/D.C./		TSANIRAS et al., "Generating Pancreatic β-cells From Embryonic Stem Cells by Manipulating Signaling Pathways", April, 2010.	
/D.C./		GUO et al., "Stem Cells to Pancreatic β-Cells: New Sources for Diabetes Cell Therapy", Endocrine Reviews, 2009, Vol. 30, no. 3, pp. 214-227.	
/D.C./		EDLUND, "Pancreatic Organogenesis-Developmental Mechanisms and Implications for Therapy", Nature Reviews, July 2002, Vol. 3, pp. 524-532.	
/D.C./		BRUN et al., "The Diabetes-linked Transcription Factor Pax4 is Expressed in Human Pancreatic Islets and is Activated by Mitogens and GLP-1", Human Molecular Genetics, 2008, Vol. 17, no. 4, pp 478-489	
/D.C./		DOR et al., "Facultative Endocrine Progenitor Cells in the Adult Pancreas", Cell, January, 2008, pp. 183-184.	
/D.C./		LIEW et al., "PAX4 Enhances Beta-Cell Differentiation of Human Embryonic Stem Cells", PloS One, March, 2008, Vol. 3, issue 3, pp. 1-11	
/D.C./		AIRAKSINEN et al., "The GDNF Family: Signalling, Biological Functions and Therapeutic Value", Nature Reviews, May, 2002, Vol. 3, pp. 383-394	
/D.C./	1	D'AMOUR et al., "Production of Pancreatic Hormone-Expressing Endocrine Cells from Human Embryonic Stem Cells", Nature Biotechnology, November, 2006, Vol. 24, no. 11, pp. 1392-1401.	
/D.C./		LIN et al., "Enhancement of Insulin-producing Cell Differentiation from Embryonic Stem Cells Using Pax-4- nucleofection Method", World Journal of Gastroenterology, March, 2007, Vol. 13, no. 11, pp. 1672-1679	

•					
	Examiner Signature	/Deborah Crouch/	Date Considered	09/11/2010	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Unaw line through citation in not in conformance and not considered, include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, uspection gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information. including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Comments on the Amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Comments on the Chief Information Chief Information Comments on the Chief Information C